These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

in acetylcholine receptor antibody positive (AChR+) patients after 12 weeks. Immunovant reported that MG patients who received the weekly 680mg subcutaneous dose of batoclimab achieved a 5.6 ...

The primary endpoint of the study was mean change from baseline in MG-ADL in acetylcholine receptor antibody positive (AChR+) participants at Week 12 (end of Period 1). About the Phase 2b Study in ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase 2b study in chronic inflammatory ...

score in acetylcholine receptor antibody positive (AChR+) participants. Participants entering the study and randomized to 680mg of batoclimab given weekly by subcutaneous injection achieved a 5.6 ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with ...